Top Markets
#1 TENDIES TENDIES +42.50%
#2 ICON ICON +27.31%
#3 Threshold Network Threshold Network +26.12%
#4 Cash Cat Cash Cat +25.97%
#5 Asteroid Shiba Asteroid Shiba +17.20%
#6 OSK OSK +15.67%
#7 MarsCoin MarsCoin +12.17%
#8 Ape and Pepe Ape and Pepe +9.71%
#9 Pirate Chain Pirate Chain +9.26%
#10 Kite Kite +9.02%
Coin of the day
TENDIES TENDIES
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
NervGen Pharma Corp. NervGen Pharma Corp.

NervGen Pharma Corp.

NGEN
Clasificación en acciones #16728
NervGen Pharma Corp., along with its affiliated entities, is a pharmaceutical... NervGen Pharma Corp., along with its affiliated entities, is a pharmaceutical company dedicated to discovering, advancing, and commercializing innovative drug therapies for neurological conditions involving nerve damage. Its flagship investigational therapy, NVG-291, is currently undergoing Phase 1 clinical trials, targeting significant neurological disorders such as spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. NervGen has also secured an exclusive licensing agreement with Case Western Reserve University. This partnership enables the company to research, advance, and commercialize a proprietary technology holding considerable therapeutic promise for SCI and a range of other nerve-related ailments. Established in 2017, NervGen Pharma Corp. maintains its headquarters in Vancouver, Canada.
Precio por acción
$3.78
Última sincronización: 2026-03-17
Capitalización bursátil
$276.54M
Cambio (1 día)
0.00%
Cambio (1 año)
45.53%
País
CA
Comercio NervGen Pharma Corp. (NGEN)

Categoría

Healthcare
Ingresos de NervGen Pharma Corp. (NGEN)
Ingresos en Sep 2026 TTM: 0
Según los últimos informes financieros de NervGen Pharma Corp., los ingresos actuales de la empresa (TTM) son 0. En 2026, la empresa obtuvo unos ingresos de 0 igual a los ingresos del año 2026, que fueron de 0. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de NervGen Pharma Corp. desde 2026 hasta 2026
Ingresos al final de cada año
Año Ingresos Cambiar
Not enough data for the provided dates.
Ingresos de empresas similares o competidoras
Empresa Ingresos Diferencia de ingresos País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH